Sales of Sinovac's Hepatitis Vaccine Suspended Following Baby's Death

According to a report in Interfax-China, sales of Sinovac Biotech’s (SVA) hepatitis A vaccine Healive have been suspended in Beijing's Fengtai district, following the death of a two-year-old infant.

Details remain sketchy. Sinovac has not released its official reaction to the action, which has not received wide coverage in the U.S., where Sinovac is traded. Healive is by far the most important revenue-producing product for Sinovac. It was responsible for 78% of Sinovac’s Q3 sales.

Sinovac’s shares dropped 12 cents to $1.03 in moderately heavy trading early Monday.

Disclosure: none.